Treatment responses
tumor, anaplastic ependymoma, HL, thymoma, Ewing’s sarcoma, PD, NK/T lymphoma, tumors
DISEASE PROGRESSION, TUMOR, EPITHELIOID SARCOMA, IMMUNE HEPATITIS, THYMOMA, PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA, MYASTHENIA GRAVIS, REMISSION, ATYPICAL CHOROID PLEXUS PAPILLOMA, TUMORS, DIFFUSE LARGE B-CELL LYMPHOMA
Among 17 patients with other types of tumors, referred to as “except-HL” tumors, 2 CR (NK/T lymphoma and anaplastic ependymoma), 3 PR (1 diffuse large B-cell lymphoma, 1 Ewing’s sarcoma, and 1 thymoma) and 3 SD (1 epithelioid sarcoma, 1 atypical choroid plexus papilloma, and 1 primary mediastinal large B-cell lymphoma) were observed, as evaluated by the investigator following RECIST v1.1 criteria (Fig. Anti-tumor activity of sintilimab according to RECIST version 1.1. The waterfall plot shows the best percentage reduction in tumor burden from baseline. Included patients were those with relapsed or refractory HL (10 patients) or any tumor type except HL (15 patients). Each bar represents an individual patient. Dashed lines at a 20% increase and a 30% decrease serve as the thresholds for defining PD and PR, respectively, in accordance with RECIST 1.1 criteriaAntitumor activityIn a specific case, a 14-year-old boy was diagnosed with thymoma and myasthenia gravis. The tumor did not respond after receiving multiple chemotherapies (cyclophosphamide, cisplatin, and pirarubicin). WES revealed high expression of PD-L1 with a tumor proportion score (TPS) score of 98%. Consequently, he was enrolled to receive sintilimab treatment. After one cycle of treatment, the patient developed grade 3 immune hepatitis and discontinued anti-PD-1 therapy. The patient experienced pseudoprogression, as the tumor initially showed progression, but later the efficacy was evaluated as partial remission on computed tomography findings (Supplementary Fig. By the cutoff date, 24 patients had discontinued their treatment. Among this group, there were seven cases of patient mortality during the follow-up period, and none of these were attributed to the intervention administered in the study. Three patients remained in the study. Three CR patients (2 HL and 1 NK/T lymphoma) voluntarily discontinued treatment after maintaining CR for more than three months. Two HL patients, with 1 PR and 1 SD patient, discontinued treatment after two cycles of sintilimab due to the decision to combine it with chemotherapy. One HL patient with PR discontinued treatment to prepare for hematopoietic stem cell transplantation. Among all 27 patients, the median PFS was not reached. The median OS was not reached for the overall population, HL patients, or patients with other types of tumors except HL (Fig. Kaplan‒Meier analysis of overall survival estimates in patients with relapsed or refractory HL (Kaplan‒Meier estimates of disease progression survival in patients with relapsed or refractory HL (